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Abstract: Methamphetamine (METH) is a widely abused substance world over. Currently, there is no effective pharma- 
cotherapy to treat its effects. This necessitates identification of potential novel therapeutic targets. METH interacts with  
sigma () receptors at physiologically relevant micromolar concentrations. In addition,  receptors are present in organs  
like the brain, heart, and lungs at which METH acts. Additionally,  receptors have been implicated in various acute  
and subchronic effects like locomotor stimulation, development of sensitization and neurotoxicity, where  receptor   
antagonists attenuate these effects.  Receptors may also have a role in METH-induced psychiatric complications such  
as depression, psychosis, cognitive and motor deficits. The neurotoxic effects of METH, which are cause for concern,  
can be prevented by  receptor antagonists in mice. Mechanistically, METH-induced neurotoxicity involves factors like  
dopamine release, oxidative stress, endoplasmic reticulum stress, activation of mitochondrial death cascades, glutamate  
release, apoptosis, microglial activation, and hyperthermia. This review compiles studies from the literature that suggests  
an important role for  receptors in many of the mechanisms of METH-induced neurotoxicity.  
Keywords: Methamphetamine, sigma receptors, oxidative stress, endoplasmic reticulum, mitochondria, neurotoxicity, dopa-
mine, glutamate. 
METHAMPHETAMINE (METH): A DRUG OF 
ABUSE 
  Methamphetamine (METH) is a widely abused substance 
due to its ease of synthesis from over the counter drugs and 
its long duration of action [1]. Due to these factors, it ranks 
second worldwide after Cannabis as the most extensively 
abused drug, with an estimated 15-16 million users [2]. 
Apart from its immediate stimulant effects such as euphoria 
and enhanced energy, METH causes harmful effects upon 
exposure to repeated or large doses. Some of these harmful 
effects include hyperthermia, addiction, altered neurological 
and cognitive functions, psychosis, depression, and neurode-
generation [2].  
  The neurodegenerative effects are causes of concern as 
neuroimaging and postmortem studies in humans depict 
damage to dopaminergic and serotonergic systems, which 
can be measured as depletions in dopamine transporters 
(DAT), serotonin transporters (SERT), and dopamine and 
serotonin levels [2]. There is evidence that these neurode-
generative effects are implicated in some of the psychiatric 
symptoms observed due to METH [3]. However, the mecha-
nisms underlying these neurodegenerative effects are still not 
clearly understood. Also, no effective treatment exists for 
these effects of METH.  
METH AND SIGMA RECEPTORS 
  Exploration of a novel target to develop medications 
against, and to better understand the mechanisms of METH-
induced neurotoxicity led to the discovery that METH   
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interacts with sigma () receptors at physiologically relevant 
concentrations [4].  Receptors are a unique group of drug 
binding sites [5]. They are found extensively in the brain and 
periphery [5], with two established subtypes: -1 and -2. 
METH binds to -1 receptors with a Ki of 2 μM and -2 re-
ceptors with a Ki of 47 μM [4]. -1 Receptors have been 
cloned and are not homologous to any known protein except 
for sharing 30% homology with fungal sterol isomerase [5]. 
Following the binding of ligands, -1 receptors have been 
shown to operate via protein-protein interactions and translo-
cation between subcellular compartments through chaper-
one-like functions [5-7]. In contrast, -2 receptors have not 
yet been cloned. They are localized in lipid rafts, plasma 
membrane, endoplasmic reticulum (ER), mitochondria, and 
lysosomes of cells [8, 9]. -2 Receptors are highly upregu-
lated in tumor cell lines and have a role in cell death signal-
ing via sphingolipid products [10].  
   Receptors seem to play an important role in many of 
the effects of METH. They are present in the organs that 
mediate the actions of METH (e.g. brain, heart, lungs) [5]. In 
the brain, METH acts primarily on the dopaminergic system 
to cause acute locomotor stimulant, subchronic sensitized, 
and neurotoxic effects.  Receptors are present on dopa-
minergic neurons and their activation stimulates dopamine 
synthesis and release [11-13]. -2 Receptors modulate DAT 
and the release of dopamine via protein kinase C (PKC) and 
Ca
2+-calmodulin systems [14].  
  -1 Receptor antisense and antagonists have been shown 
to block the acute locomotor stimulant effects of METH [4]. 
Repeated administration or self administration of METH has 
been shown to upregulate -1 receptor protein and mRNA in  
various brain regions including the substantia nigra, frontal 
cortex, cerebellum, midbrain, and hippocampus [15, 16]. 
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(4-chlorophenyl)-3-[4-(2-methoxyethyl)piperazin-1-yl]methyl-
2-pyrrolidinone-L-tartrate) and BMY14802 (alpha-(4-
fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-butanol) 
prevent the development of behavioral sensitization to 
METH [17, 18].  
  Clinically, METH users display cognitive deficits, de-
pression, anxiety, psychotic symptoms, and motor deficits 
similar to Parkinson’s disease [2]. Apart from being present 
in brain regions associated with these disorders [19, 20],  
receptors have also been implicated in cognitive dysfunc-
tions, depression, anxiety, schizophrenia, and Parkinson’s 
disease [21, 22]. Some of the observed psychiatric symptoms 
especially cognitive dysfunction seems to arise from the neu-
rodegenerative effects of METH [3]. 
  METH causes neurodegenerative/neurotoxic effects fol-
lowing high or repeated dosing, which has been manifested 
as dopaminergic and serotonergic nerve terminal degenera-
tion (measured as depletions in neurotransmitter levels and 
decreases in monoamine transporter levels) as well as more 
recently, apoptotic cell death [23]. These effects have been 
observed in humans as well as in animal models involving 
mice, rats, and monkeys [2].  Receptor antagonists like 
AC927 (N-phenethylpiperidine oxalate) prevent the neuro-
toxic effects of METH in Swiss Webster mice, including 
METH-induced depletions in dopamine and DAT levels in 
striatal brain regions [24]. 
  Mechanistically, the neurotoxic effects of METH seem to 
involve the activation of certain events such as dopamine 
release, oxidative stress, ER stress and mitochondrial death 
cascades, excitotoxicity, microglial activation, and hyper-
thermia [2]. In addition, compelling evidence in the literature 
indicate that apart from being a direct target of METH,  
receptors play an important role in the modulation of other 
neurotransmitter systems and downstream events involved in 
METH-induced neurotoxicity. Systematic mechanistic stud-
ies, however, have not been conducted in the context of 
METH. The rest of the review is focused on the various 
downstream events where  receptors may potentially modu-
late the effects of METH. In those instances where the role 
of an individual subtype of  receptor is known, the subtype 
is specified. Otherwise, the term  receptor, with no subtype 
designation, is used. 
Dopamine 
  METH acts through DAT and vesicular monoamine 
transporter 2 (VMAT2) to cause excessive release of dopa-
mine into the cytoplasm and synapse [25, 26], which   
is thought to be one of the initiating factors in METH’s   
neurotoxic cascade.  Receptor agonists have been shown   
to facilitate dopamine release, through both -1 and -2  
receptors [11-14]. 
Reactive Oxygen Species 
  After this excessive dopamine release, auto-oxidation 
reactions lead to the formation of harmful reactive oxygen 
species (ROS) including dopamine quinones, superoxide 
radicals, hydroxyl radicals, and hydrogen peroxide [2]. 
These ROS can damage neurons and surrounding cells via 
oxidative damage to cellular components such as lipids, pro-
teins, and DNA [2].  
  -2 Receptor activation has been shown to cause the re-
lease of ROS in tumor cells [27]. In contrast,  receptor an-
tagonism affords protection in brain ischemia, a condition in 
which ROS are generated [28]. These studies indicate a po-
tential connection between  receptors and oxidative stress 
mechanisms of METH-induced neurotoxicity.  
ER Stress, Calcium and Mitochondrial Death Cascades 
  METH causes ER stress and activation of mitochondrial 
death cascades partly due to increases in oxidative stress in 
the cell [29]. ER stress causes disturbances in cellular cal-
cium homeostasis [30]. ER stress and calcium dysregulation 
contributes to cell death observed due to METH [29]. Sus-
tained ER stress and excessive calcium efflux in turn can 
contribute to METH-induced apoptosis via  mitochondrial 
pore permeabilization [29, 31].  
   Receptors are located on the ER and mitochondria [8, 
22]. -1 Receptors have been shown to function as chaper-
ones at the mitochondrial-associated ER membrane (MAM). 
At MAM, -1 receptors play an important role in regulating 
calcium levels via inositol triphosphate (IP3) receptors and 
maintaining homeostasis in the cell against oxidative stress 
and perturbations in calcium [7]. On the other hand, -2 re-
ceptor activation has been shown to cause a biphasic flux of 
calcium from the ER and mitochondrial stores which leads to 
apoptotic cell death [32, 33]. 
Apoptosis 
  METH causes apoptotic cell death in certain brain areas 
including the striatum, cortex, and hippocampus [34]. The 
apoptotic process can be either caspase-dependent or inde-
pendent [29]. 
  -2 Receptor activation has been shown to cause apopto-
sis in tumor cells via  caspase-dependent and independent 
processes, depending on the cell type [10, 35]. -2 Receptor 
activation has also been shown to cause apoptotic cell death 
in tumor cells via alterations in cellular sphingolipid levels 
[36]. In contrast, -1 receptor agonists have been shown to 
have neuroprotective effects by regulating intracellular cal-
cium levels and preventing activation of pro-apoptotic genes 
in retinal ganglion cells [37]. -1 Receptor agonists have 
also been reported to preserve protective genes like bcl-2 in a 
cerebral focal ischemia model [38]. 
Glutamate and Excitotoxicity 
  Glutamate release and excitotoxic mechanisms have also 
been implicated in METH-induced neurotoxicity [2].  Re-
ceptors have an important role in modulating the glutamater-
gic N–methyl-D-aspartate (NMDA) system and display neu-
roprotective effects against excitotoxic mechanisms in 
ischemic stroke models, midbrain and cortical dopaminergic 
neurons, and retinal ganglion cells [39-42]. 
Microglial Activation 
  Recent studies have underscored the role of accessory 
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Microglial activation has been observed in areas of the brain 
that have been damaged by METH [43, 44]. Drugs that at-
tenuate neurotoxic effects also suppress microglial activation 
[2]. However, the mechanisms by which microglia influence 
METH’s neurotoxic effects are still not very clear. Release 
of cytokines and ROS have been suggested as possible con-
tributing mechanisms [2].  Receptors are found on micro-
glia and the  receptor agonist di-o-tolylguanidine has been 
shown to suppress microglial activation [45]; the subtype 
most likely involved in this effect is -1, although experi- 
ments to specifically address this issue have yet to be 
performed.  
Hyperthermia 
  METH increases body temperature, which is known to 
exacerbate neurotoxic effects [46].  Receptors are present in 
the hypothalamus and can modulate body temperature [19, 
47].   Receptor antagonists have been shown to decrease 
METH-induced hyperthermia, which is consistent with an 
overall important and beneficial role for mitigating detrimen-
tal effects of METH. However, it is important to note that 
decreasing body temperature is not the only mechanism by 
which  receptors afford neuroprotective effects. This is be-
cause, firstly,  receptors have already been shown to have 
an important role in cell death processes/mechanisms, some 
of which are also involved in METH-induced neurotoxicity. 
Secondly,  receptor antagonists have been shown to attenu-
ate neurotoxic effects in a cell culture system where the tem-
perature was kept constant [24]. Thirdly, although tempera-
ture seems to play an important role in the neurotoxic effects 
of METH, it is not the only mechanism of METH’s toxicity. 
Elevated ambient temperature by itself does not show toxic-
ity [46]; pharmacological manipulations like nNOS inhibitor 
attenuate toxicity but do not decrease temperature [48]; and 
finally, reserpine causes hypothermia and reduces METH-
induced hyperthermia but does not attenuate neurotoxicity 
associated with METH [49]. 
  In summary, the available information indicates that -2 
receptor agonism and -1 receptor antagonism mediate cyto-
toxicity. Therefore, at neurotoxic doses, METH most likely 
produces its damage through -2 receptor agonism. At low 
stimulant doses, METH appears to act as an agonist at -1 
receptors, with pharmacological antagonists and antisense 
oligonucleotides attenuating METH-induced locomotor ac-
tivity [4]. Although -1 agonism would indicate the potential 
for neuroprotective effects, at higher concentrations, METH 
does not produce functional effects like a typical -1 recep-
tor agonist as demonstrated by a recent study of its mecha-
nism as a chaperone [7]. When considered together, the data 
suggest that with regard to the actions of METH, cytotoxic 
effects through -2 receptors dominates over any protective 
actions that may be afforded via the -1 subtype. Although, 
additional studies to further delineate specific mechanisms 
are still needed, the information in the literature suggest  
receptors, particularly the -2 subtype, as a very promising 
target for developing medications against and understanding 
the mechanism of METH-induced neurotoxicity along with 
the other adverse effects.  
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